Early Dehiscence Markers in Ovarian Cancer Surgery (EDMOCS)

Vall d'Hebron University Hospital (HUVH)

Status: Completed

Conditions: Ovarian Neoplasms Malignant; Anastomotic Leak

Treatments: Diagnostic Test: Blood test

Study type: Observational

Funder types: Other

Identifiers

NCT03131492

PR(AMI)68/2017

Details and patient eligibility

About

EDMOCS trial pretends to evaluate if C-reactive protein (CRP) and procalcitonin (PCT) can predict intestinal anastomotic leaks before early discharge in advanced ovarian cancer surgery requiring intestinal resection. These markers have already been positively tested in colorectal cancer surgery, but not yet in ovarian surgery.

Patients undergoing intestinal resection in ovarian cancer surgery will be included. C-reactive protein and PCT will be measured pre-operatively, and on the second, fourth and sixth postoperative day. Thirty-day readmissions, re-operations and mortality will be recorded.

Enrollment: 92 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ovarian cancer stage III-IV
• Intestinal resection needed

Exclusion criteria

• Infection diagnosed at time of surgery.
• Urgent surgery